Current Headlines

  1. Scientists ‘Snip’ HIV From Cultured Human Cells
    7/29/2014

    Scientists from Temple University reported that they have designed a new approach to remove HIV from human cells growing in culture through genome editing.

  2. Gilead’s Zydelig Approved By FDA For 3 Blood Cancers
    7/29/2014
    The U.S. Food and Drug Administration (FDA) announced that it has approved Gilead Sciences’ Zydelig for the treatment of three types of blood cancers.
  3. AstraZeneca, Qiagen Partner For IRESS Companion Test In NSCLC
    7/29/2014
    Netherlands-based sample and assays technologies company Qiagen announced that it has entered into partnership with British pharma giant AstraZeneca for the development and marketing of a liquid biopsy-based companion diagnostic for Iressa, AstraZeneca’s drug for non-small cell lung cancer (NSCLC).
  4. Researchers Pinpoint Mechanism In Malaria Drug Resistance
    7/28/2014

    Researchers from the Washington University School of Medicine in St. Louis reported their discovery of a mechanism behind malaria parasites’ drug resistance. The discovery may also apply to other infectious diseases, such as tuberculosis and bacterial infections.

  5. CHMP Recommends Pharmacyclics’ Imbruvica For 2 Blood Cancers
    7/28/2014

    Pharmacyclics announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for its marketing authorization application for Imbruvica (ibrutinib) in the EU.

  6. Shire Partners With ArmaGen On AGT-182 For Hunter Syndrome
    7/25/2014

    Shire announced in a press release that it has partnered with ArmaGen, a U.S. biotechnology company, on AGT-182 for Hunter syndrome. The investigational enzyme replacement therapy (ERT) has potential in treating the central nervous system (CNS) symptoms of the rare disease. Shire states that the new collaboration demonstrates its commitment to the Hunter syndrome community and strengthens its rare disease pipeline.

  7. Aarhus University, Bionor Pharma Use Celgene’s Istodax To Lure HIV
    7/25/2014

    Researchers from Aarhus University and Bionor Pharma presented an abstract at the Aids 2014 congress in Melbourne regarding a small study that used Celgene’s Istodax (romidepsin) to lure HIV hidden in reservoirs in the body. Driving the virus into the open makes it susceptible to antiretroviral therapy. Medscape reports that Sharon Lewin, MD, co-chair of the meeting organizing committee, said the results were the first of its kind and significant; waking up the long-lived, sleeping forms of the virus and making it leave the cell is a big step. Steven Deeks, MD, from the University of California at San Francisco, said, "I think this is the single most important advance we've heard of at this meeting, and it's going to have a huge impact in the future."

  8. Two Australian Patients Reported HIV-Free After Cancer Treatment
    7/25/2014

    Two male Australian patients were reported to be ostensibly free from Human Immuno-deficiency Virus (HIV) following stem cell transplants to treat cancer.

  9. BCM Engineers Virus-Specific T Cells Against 5 Infections
    7/25/2014
    Scientists from the Baylor College of Medicine in Houston recently reported that they have identified a technique to rapidly generate virus-specific T cells (VSTs) against five infections that affect immunocompromised patients following bone marrow or stem cells transplantation.
  10. Meissner’s SGT (Single-Use Gauge Tee) Allows Secure Pressure Monitoring Within A Single-Use System
    7/25/2014

    Meissner’s SGT provides high accuracy pressure monitoring functionality for pre-sterilized single-use systems.

Newsletter Signup
Newsletter Signup